Technology
Health
Biotechnology

EDAP TMS

$2.98
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell EDAP TMS and other stocks, options, ETFs, and crypto commission-free!

About

EDAP TMS SA develops, produces and markets minimally invasive medical devices for urological diseases. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Read More Ablatherm-HIFU is generally recommended for patients with localized prostate cancer who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment, Ablatherm-HIFU is approved and commercialized in Europe as a treatment for prostate cancer and is currently under regulatory review in the U.S. In March 2013, the company introduced a new innovative HIFU device, the Focal One dedicated to focal therapy of prostate cancer. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Employees
200
Headquarters
Vaulx-en-Velin, Rhone-Alpes
Founded
1979
Market Cap
86.41M
Price-Earnings Ratio
Dividend Yield
Average Volume
204.94K
High Today
$3.00
Low Today
$2.85
Open Price
$3.00
Volume
3.32K
52 Week High
$4.25
52 Week Low
$1.35

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical Devices
Medical
Therapy
Europe (Non-UK)

News

Simply Wall StMar 8

Did Changing Sentiment Drive EDAP TMS’s Share Price Down By 34%?

While not a mind-blowing move, it is good to see that the EDAP TMS S.A. (NASDAQ:EDAP) share price has gained 10% in the last three months.

0
Associated PressMar 4

EDAP TMS SA : HIFU Pioneer Houston Methodist Hospital Acquires EDAP’s Next Generation Focal One HIFU System

Houston Methodist’s Upgrade from Ablatherm to Focal One Reinforces EDAP’s Position as a Leading HIFU Innovator LYON, France, March 4, 2019 -- EDAP TMS SA (Nasdaq: EDAP) -- Houston Methodist Hospital, one of the first hospitals in the U.S. to offer Ablatherm® Robotic High Intensity Focused Ultrasound (HIFU) for patients with localized prostate cancer, has acquired Focal One®, the most advanced HIFU technology available today. Houston Methodist Hospital initially invested in EDAP’s first generation HIFU sys...

16

Earnings

-$0.07
-$0.04
-$0.01
$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
Expected Mar 26, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.